Laboratoires Théa to acquire sepofarsen and ultevursen assets from ProQR Therapeutics for €13m.

Laboratoires Théa, an independent pharmaceutical company specialized in research,development and commercialization of eyecare products, agreed to acquire sepofarsen and ultevursen assets from ProQR Therapeutics, a company dedicated to changing lives through transformative RNA therapies, for €13m. “Théa’s proven expertise in the research, development, and commercialization of eye care products makes them the ideal company to continue the development of sepofarsen and ultevursen for patients with rare genetic eye diseases. We look forward to continuing to advance our Axiomer RNA editing platform, with an initial focus on targets for cholestatic and cardiovascular diseases, as we seek to develop a new class of therapies for patients with high unmet need," Daniel A. de Boer, ProQR Founder and CEO.